A08648 expands New York’s Family Health Care Decisions Act framework to cover health care decisions for patients with intellectual or developmental disabilities. The bill creates a new Public Health Law section specifically addressing these patients, clarifying when surrogates may act, how capacity is presumed and determined, who must be notified, and how objections are handled when life-sustaining treatment is withdrawn or withheld. It also amends related provisions so that guardians appointed under Surrogate’s Court Procedure Act article 17-A are recognized in the health care decision hierarchy, and so that certain decisions for people with intellectual or developmental disabilities are routed to the appropriate statutory scheme rather than the general FHCDA process.
The bill also repeals and replaces Surrogate’s Court Procedure Act section 1750-b, shifting life-sustaining treatment decisions for persons with intellectual or developmental disabilities into the Public Health Law framework while preserving the role of health care proxies, nonhospital DNR rules, and other existing decision-making statutes where applicable. It adds notice requirements, including advance notice to the patient when possible, to residential facility operators or the OPWDD commissioner in some cases, and to mental hygiene legal services. It also addresses surrogate decision-making committees, MOLST and DNR forms, and directs the Department of Health to work with the Office of Mental Health and the Office for People with Developmental Disabilities on implementing regulations.
The bill’s practical impact is to create a more detailed and disability-specific process for end-of-life and other health care decisions, while integrating those decisions into existing New York health law. It would affect hospitals, residential facilities, practitioners, guardians, family members, mental hygiene legal services, OPWDD, and people with intellectual or developmental disabilities by setting out who can decide, when notice is required, and how disputes are resolved. It also broadens the surrogate priority list and clarifies that decisions for this population are not to be influenced by assumptions about diminished rights or dignity.
Because there are no recorded votes or committee transcripts in the provided material, there is no documented legislative debate to gauge support or opposition. Based on the bill text, the measure appears designed to strengthen procedural protections and clarify authority for treatment decisions, suggesting a generally protective and reform-oriented intent. The main policy tension embedded in the bill is between ensuring robust safeguards, notice, and review for vulnerable patients and avoiding delays in urgent medical decisions, especially those involving orders not to resuscitate or withdrawal of life-sustaining treatment.
The bill would amend the Public Health Law and repeal/rewrite Surrogate’s Court Procedure Act section 1750-b to create a separate legal pathway for health care decisions involving people with intellectual or developmental disabilities. It would recognize article 17-A guardians in the surrogate hierarchy, add a new disability-specific section governing notice, objections, and life-sustaining treatment decisions, and require coordination with OMH and OPWDD in rulemaking. It also updates related definitions and MOLST/DNR provisions to align with the new framework and to ensure these decisions are handled under the appropriate statute rather than the general FHCDA alone.
No votes or committee transcripts were provided, so there is no direct record of legislative sentiment from debate or roll call. The bill’s structure and caption indicate a generally supportive policy goal: extending decision-making protections and clarifying procedures for a population with intellectual or developmental disabilities. The text suggests an emphasis on patient rights, due process, and clearer authority for surrogates and guardians, while also preserving emergency medical flexibility.
The likely points of contention are procedural safeguards versus speed and finality in end-of-life decisions. The bill requires notice to the patient when possible, to facility officials or state agencies, and to mental hygiene legal services, and it allows objections to suspend decisions in some cases, which may be viewed as necessary protections by disability advocates but as potential delays by providers or families seeking timely care. Another possible area of dispute is the bill’s treatment of article 17-A guardians and surrogate decision-making committees, including how much authority they should have and how disputes should be reviewed. The bill also expressly excludes decisions from being influenced by assumptions about disability, reflecting a rights-based approach that may be central to the bill’s support and any opposition.